Anebulo Pharmaceuticals Stock Performance
| ANEB Stock | USD 1.66 0.08 5.06% |
Anebulo Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.21, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Anebulo Pharmaceuticals will likely underperform. Anebulo Pharmaceuticals right now shows a risk of 6.9%. Please confirm Anebulo Pharmaceuticals semi deviation, jensen alpha, maximum drawdown, as well as the relationship between the coefficient of variation and sortino ratio , to decide if Anebulo Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Anebulo Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat fragile technical and fundamental indicators, Anebulo Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
1 | Acquisition by Cunningham, Richard Anthony of 254433 shares of Anebulo Pharmaceuticals at 1.56 subject to Rule 16b-3 | 12/24/2024 |
2 | Insider Trading | 12/27/2024 |
3 | Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates | 02/14/2025 |
4 | Anebulo Pharmaceuticals Reports Fiscal Q2 2025 Results - TipRanks | 02/18/2025 |
5 | Benchmark maintains Speculative Buy on Anebulo stock, target at 8 - Investing.com | 02/25/2025 |
6 | Acquisition by English Aron R. of 10101010 shares of Anebulo Pharmaceuticals at 0.99 subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 11.2 M |
Anebulo |
Anebulo Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 162.00 in Anebulo Pharmaceuticals on December 25, 2024 and sell it today you would lose (4.00) from holding Anebulo Pharmaceuticals or give up 2.47% of portfolio value over 90 days. Anebulo Pharmaceuticals is currently generating 0.1845% in daily expected returns and assumes 6.8989% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than Anebulo, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Anebulo Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Anebulo Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Anebulo Pharmaceuticals, and traders can use it to determine the average amount a Anebulo Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0268
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ANEB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.9 actual daily | 61 61% of assets are less volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Anebulo Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Anebulo Pharmaceuticals by adding it to a well-diversified portfolio.
Anebulo Pharmaceuticals Fundamentals Growth
Anebulo Stock prices reflect investors' perceptions of the future prospects and financial health of Anebulo Pharmaceuticals, and Anebulo Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Anebulo Stock performance.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 49.92 M | ||||
| Shares Outstanding | 25.93 M | ||||
| Price To Book | 4.34 X | ||||
| EBITDA | (8.05 M) | ||||
| Net Income | (8.2 M) | ||||
| Cash And Equivalents | 14.55 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 260.58 K | ||||
| Current Ratio | 30.40 X | ||||
| Book Value Per Share | 0.15 X | ||||
| Cash Flow From Operations | (8.09 M) | ||||
| Earnings Per Share | (0.32) X | ||||
| Market Capitalization | 42.79 M | ||||
| Total Asset | 4.07 M | ||||
| Retained Earnings | (65.4 M) | ||||
| Working Capital | 3.25 M | ||||
About Anebulo Pharmaceuticals Performance
By analyzing Anebulo Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Anebulo Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Anebulo Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Anebulo Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.32) | (2.20) | |
| Return On Capital Employed | (2.51) | (2.38) | |
| Return On Assets | (2.32) | (2.20) | |
| Return On Equity | (2.47) | (2.35) |
Things to note about Anebulo Pharmaceuticals performance evaluation
Checking the ongoing alerts about Anebulo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Anebulo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Anebulo Pharmaceuticals had very high historical volatility over the last 90 days | |
| Anebulo Pharmaceuticals may become a speculative penny stock | |
| Net Loss for the year was (8.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Anebulo Pharmaceuticals currently holds about 14.55 M in cash with (8.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Anebulo Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Acquisition by English Aron R. of 10101010 shares of Anebulo Pharmaceuticals at 0.99 subject to Rule 16b-3 |
- Analyzing Anebulo Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Anebulo Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Anebulo Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Anebulo Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Anebulo Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Anebulo Pharmaceuticals' stock. These opinions can provide insight into Anebulo Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Anebulo Stock analysis
When running Anebulo Pharmaceuticals' price analysis, check to measure Anebulo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anebulo Pharmaceuticals is operating at the current time. Most of Anebulo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Anebulo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anebulo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Anebulo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |